

# Can Antibiotic Treatment Time For *Mycobacterium ulcerans* Infection Be Reduced?

Brodie Tweeddale<sup>1,2</sup> \*, Fiona Collier<sup>1</sup>, Nilakshi Waidyatillake<sup>2,3</sup>, Eugene Athan<sup>1,2</sup> and Daniel O'Brien<sup>2,4</sup>

<sup>1</sup> Geelong Centre for Emerging Infectious Diseases, <sup>2</sup>Infectious Diseases Department, Barwon Health, <sup>3</sup>Allergy & Lung Health Unit, University of Melbourne, <sup>4</sup>Department of Medicine and Infectious Diseases, Royal Melbourne Hospital, University of Melbourne

\* Presenting Author: brodie.tweed@icloud.com

## Background & Aims

*Mycobacterium ulcerans* disease, known as the Buruli ulcer, is a necrotising infection of the skin and subcutaneous tissue<sup>1</sup>. Significant toxicities are commonly associated with the currently recommended eight-week antibiotic treatment regimens, with up to 22% of patients experiencing an antibiotic complication severe enough to warrant cessation of at least one antibiotic<sup>2</sup>. We aimed to investigate the antibiotic duration required to achieve sterilisation of *M. ulcerans* disease lesions and the influence of patient characteristics on this outcome.

## Methods

Prospective observational *M. ulcerans* case data was examined from patients treated with antibiotics prior to surgery and post-excisional culture assessment at Barwon Health, Victoria, from 25/5/1998 to 30/6/2019. Unsuccessful lesion sterilisation was measured by a positive *M. ulcerans* culture. A chi-square test of goodness-of-fit examined the association between antibiotic duration before surgery and culture positive outcome. To assess influence of baseline characteristics on culture outcome, a multivariate Cox regression analysis was performed.

## Results

Ninety-two patients were included with a median age of 60 years (IQR 28-74.5) and 51 (55.4%) were male. Rifampicin-based regimens were predominantly used in combination with clarithromycin (47.8%) and ciprofloxacin (46.7%). Median duration of antibiotic treatment before surgery was 23 days (IQR 8.0-45.5) (Table 1).

The proportion of patients with a positive *M. ulcerans* culture following 1-2 weeks of antibiotics was 51.6%, after 2-4 weeks was 27.3%, and there were no culture positive results after 2.7 weeks of antibiotics. A significant association existed between antibiotic duration before surgery and culture positive outcome ( $p < 0.001$ ) (Figure 1A & B). The patient baseline variable 'age' ( $p = 0.06$ ) and immune suppression ( $p = 0.07$ ) showed weak evidence of an influence on culture positivity (Table 2).


Table 1: Baseline Characteristics

Treatment Cohort (n=92)		Mean ± SD (Range)
Variable	n (%)	
<b>Gender</b>		
• Male	51 (55.43)	
• Female	41 (44.57)	
<b>Age (years)</b>		51.8 ± 26.4 (2-91) Median = 60 (IQR 28-74.5)
• 0-19	19 (20.7)	
• 20-59	26 (28.3)	
• ≥ 60	47 (51.1)	
<b>WHO Category of Lesions</b>		
• 1	54 (58.7)	
• 2	16 (17.39)	
• 3	22 (23.91)	
<b>Lesion Type</b>		
• Nodule	4 (4.4)	
• Oedematous	24 (26.1)	
• Plaque	4 (4.4)	
• Ulcer	60 (65.2)	
<b>Antibiotic duration (days)</b>		29.4 ± 24.2 (1-89)
<b>Lesion Site</b>		
• Upper limb	29 (31.5%)	
• Lower limb	61 (66.3%)	
• Head/Trunk	2 (2.2%)	
<b>Number of antibiotics</b>		
• 2	79 (85.9%)	
• 3+	13 (14.1%)	
<b>Weight (kg)</b>		
• 0-90	21 (22.8%)	
• ≥ 90	8 (8.7%)	
• Missing	63 (68.5%)	
<b>Antibiotic regimen</b>		
• RC1a	44 (47.8%)	
• RCp	43 (46.7%)	
• Other	5 (5.4%)	


Table 2: Cox regression model with adjusted and unadjusted associations between identified variables and rates of positive *M. ulcerans* culture.

Variable	Failures (%)	Follow-up (days)	Rate per 100-person days (95% CI)	Crude hazard ratio (95% CI)	p-value	Adjusted hazard ratio (95% CI)	p-value
<b>Gender</b>							
Female	10 (24.4)	1115	9.0 (4.83,16.67)	1	0.97	1	0.86
Male	12 (23.5)	1587	7.6 (4.5,14.1)	1.0 (0.4,2.3)		0.9 (0.4,2.2)	
<b>Age (years)</b>							
0-15	1 (7.1)	603	1.7 (0.2-11.8)	1	0.14	1	0.07
16-64	9 (23.1)	995	9.0 (4.7,17.4)	4.1 (0.5,32.6)		4.3 (0.5,34.5)	
≥65	12 (30.8)	1104	10.9 (6.2,19.1)	5.1 (0.7,39.3)		6.6 (0.8,50.8)	
<b>Immune suppression</b>							
No	21 (26.3)	2351	8.9 (5.8,13.7)	1	0.16	-	0.06
Yes	1 (8.3)	351	2.8 (0.4,20.2)	0.3 (0.0,2.3)		0.2 (0.1,6)	
<b>Diabetes</b>							
No	22 (27.2)	2271	9.7 (6.4,14.7)	-	-	-	-
Yes	0 (0.0)	238	0	-	-	-	-
<b>Antibiotic regimen</b>							
RC1a	9 (20.5)	1517	5.9 (3.1,11.4)	1	0.48	-	-
RCp	12 (27.9)	1026	11.7 (6.6,20.6)	1.7 (0.7,4.0)		-	-
Other	1 (20.0)	159	6.3 (0.9,44.6)	1.0 (0.1,7.7)		-	-
<b>Weight (kg)</b>							
0-90	4 (19.1)	707	5.7 (2.1,15.1)	1	0.71	-	-
≥90	2 (25.0)	251	8.0 (2.0,31.9)	1.3 (0.2,7.3)		-	-
Missing	16 (25.4)	1744	9.2 (5.6,15.0)	1.6 (0.5,4.7)		-	-
<b>Duration of symptoms</b>							
0-42	15 (27.8)	1593	9.4 (5.7,15.6)	1	0.50	-	-
≥42	6 (16.7)	1030	5.8 (2.6,12.0)	0.6 (0.2,1.6)		-	-

A.



B.



**Figure 1: Relationship between antibiotic duration before surgery (weeks) & culture outcome.** A. The excised *M. ulcerans* lesions were cultured and the outcome (+ve/-ve) was evaluated in response to the duration of antibiotic treatment before surgery. Positive cultures were not evident after 2.7 weeks ( $p < 0.0001$ , Chi-squared test). B. A Kaplan-Meier curve showing the cumulative incidence of positive *M. ulcerans* cultures according to days of antibiotic treatment.

## Conclusions

- For this Australian cohort it appears that a significant proportion of *M. ulcerans* disease lesions can be sterilised in less than three weeks of antibiotic therapy.
- This provides the potential to significantly reduce toxicities and cost experienced by patients by reducing the duration of antibiotic treatment.

## References

1. Portaels, F, Silva, MT & Meyers, WM 2009, 'Buruli Ulcer', *Clinics In Dermatology*, vol. 27, no. 3, pp. 291-305
2. O'Brien, DP, Friedman, D, Hughes, A, Walton, A & Athan, E 2017, 'Antibiotic complications during the treatment of *Mycobacterium ulcerans* disease in Australian patients', *Internal medicine journal*, vol. 47, no. 9, pp. 1011-9